Abstraction Health

Rhodiola Rosea

Adaptogen

Also known as: Rhodiola · Arctic root · Golden root · Rosavin

🟠Weak Evidence 60 expert mentions 20 studies
C·62/100·Fair
Research Depth25/25
Study Quality11/25
Expert Consensus17/25
Claim Support9/25
How we score the evidence →

An adaptogenic herb studied for stress resistance, mental fatigue, and exercise performance. Standardized extracts contain rosavins and salidroside. Shorter studied duration than ashwagandha.

Common forms:standardized extract (3% rosavins)capsuletincture

How expert claims hold up

60 of 60 claims assessed
2Supported20Partial38Insufficient

22 of 60 assessed claims supported or partially supported by published research

Expert Consensus

Research agrees
1/5
Experts mention
1
Recommend
1
Flag caution
Andrew Huberman
Andrew Huberman Recommends Caution
Research agrees60 claims200–400milligramsstandardized extract

Evidence Summary

PubMed / NCBI·May 2026
All 20 studies
20
Studies
7
RCTs
11
Reviews

Rhodiola rosea is among the more extensively studied herbal adaptogens, with a research base spanning randomized controlled trials, systematic reviews, and meta-analyses examining its effects on stress, mood, fatigue, cognitive function, and physical performance. Compared to many other adaptogens, Rhodiola has been evaluated in human trials across multiple domains, including a WFSBP/CANMAT clinical guideline review and a systematic review on HPA axis modulation — both considered higher-quality evidence sources. RCTs in the reviewed literature have looked at specific applications such as digital eye strain, strength performance under mental fatigue, exercise performance in athletes, premenstrual syndrome, and the effects of its active compound salidroside. This breadth is noteworthy, though it does not automatically translate into robust conclusions for any single use case. Key findings suggest Rhodiola is recognized in clinical guideline contexts as a nutraceutical with some legitimate basis for consideration in mood and stress-related conditions, though it does not appear to meet the threshold for strong endorsement in any single indication based on available data. Its potential to modulate the HPA axis (the body's central stress-response system) is highlighted in a systematic review, providing a plausible biological mechanism. RCTs on physical performance — including in volleyball players and a crossover study on bench-press performance under mental fatigue — show mixed or modest results, and the research on its active isolate salidroside for exercise performance was described as exploratory. Meta-analytic evidence on milder depression includes pharmacological comparisons, suggesting some context for where Rhodiola fits, but direct head-to-head evidence remains limited. Important caveats apply. The majority of individual studies are small in sample size, short in duration, and often conducted in narrowly defined populations (e.g., healthy young male athletes), limiting generalizability to broader groups including older adults, people with chronic illness, or women outside of specific hormonal contexts. Many popular claims about Rhodiola — particularly around cognitive enhancement, energy, and long-term stress resilience — lack sufficient human trial data to be confirmed or refuted. Standardization of Rhodiola extracts across products and studies is a persistent challenge, making it difficult to compare results or translate findings to commercial supplements. What remains unknown includes optimal dosing, long-term safety beyond short study windows, and how Rhodiola compares directly to established treatments in any condition.

Read full evidence summary →

Top studies

Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2022 · Sarris J et al.
Meta-Analysis🟢
Key finding

Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.

Funded by: Industry (inferred from affiliations)
PMID: 35311615DOI: 10.1080/15622975.2021.2013041
View on PubMed

Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-Analysis.

Neuropsychopharmacology reports · 2025 · Urata M et al.
Meta-Analysis🟢
Key finding

Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-Analysis.

COI: MU has received speaker honoraria from Sumitomo Pharma and Janssen Pharmaceutical over the last 3 years. HS received grants from the Japan Society for the Promotion of Science, the Japan Research Foundation Clinical Pharmacology, and the Takeda Science Foundation, and an honorarium from Viatris, Eisai, Takeda Pharmaceutical, Otsuka Pharmaceutical, Meiji Seika Pharma, Shionogi Pharma, Yoshitomiyakuhin, Sumitomo Pharma, Kyowa Pharmaceutical, MSD, and Lundbeck Japan. HS is an Editorial Board member of Neuropsychopharmacology Reports and a corresponding author of this article. To minimize bias, they were excluded from all editorial decision‐making related to the acceptance of this article for publication. FU has received grants from the Nakatani Foundation, the Canadian Institutes of Health Research (CIHR), and the Brain & Behavior Research Foundation (BBRF); manuscript fees from Dainippon Sumitomo Pharma; and consultant fees from WCG Clinical and Uchiyama Underwriting within the past three years. TM has nothing to declare. T. Tada has received speaker honoraria from Dainippon Sumitomo Pharma and Otsuka Pharmaceutical. TU has nothing to declare. YM received an honorarium from Sumitomo Pharma, Janssen Pharmaceutical, and Meiji Seika Pharma. MM received an honorarium from Sumitomo Pharma, Yoshitomiyakuhin. MT has nothing to declare. HB received grant funding from the Japan Society for the Promotion of Science and speaker's honoraria from Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, Viatris, MSD, Meiji Seika Pharma, Eli Lilly, Yoshitomi Yakuhin, Janssen Pharmaceutical, Kyowa Pharmaceutical, Mitsubishi Tanabe Pharma, Pfizer, Esai, Takeda Pharmaceutical, Lundbeck Japan, Mochida, Sawai, Kowa, EA Pharma, and Mylan EPD. MK has received grant funding from AMED, the Japanese Ministry of Health, Labour and Welfare, the Japan Society for the Promotion of Science, SENSHIN Medical Research Foundation, the Japan Research Foundation for Clinical Pharmacology, and the Japanese Society of Clinical Neuropsychopharmacology, and consulting fees from Sumitomo Pharma Co. Ltd., Shionogi & Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Lundbeck Japan K.K., Boehringer Ingelheim Co. Ltd., and Takeda Pharmaceutical Co. Ltd.; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Sumitomo Pharma Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Meiji Seika Pharma Co. Ltd., Shionogi & Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co. Ltd., Lundbeck Japan K.K., Viatris Inc., Eisai Co. Ltd., and Kyowa Pharmaceutical Industry Co. Ltd. T. Tsuboi received grants from the Japan Society for the Promotion of Science and an honorarium from Takeda Pharmaceutical, Otsuka Pharmaceutical, Meiji Seika Pharma, Shionogi Pharma, Yoshitomiyakuhin, Sumitomo Pharma, Kyowa Pharmaceutical, MSD, Nippon Boehringer Ingelheim, Mylan EPD, Mitsubishi Tanabe Pharma, Viatris, Mochida Pharmaceutical, Janssen Pharmaceutical, TEIJIN PHARMA, and Lundbeck Japan. KW has received consultant fees from Boehringer Ingelheim, Daiichi Sankyo, Eisai, Lundbeck Japan, Luye Pharma, Mitsubishi Tanabe Pharma, Nippon Chemiphar, Ono Pharmaceutical, Otsuka Pharmaceutical, Sumitomo Pharma, and Takeda Pharmaceutical, received grant funding from AMED, the Japan Society for the Promotion of Science, and speaker honoraria from Boehringer Ingelheim, Eisai, Janssen Pharmaceutical, Kyowa Pharmaceutical, Lundbeck Japan, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Shionogi, Sumitomo Pharma, Takeda Pharmaceutical, and Viatris.
PMID: 40014460DOI: 10.1002/npr2.70008
View on PubMed

Expert Mentions

All 60 mentions
Andrew Huberman
Andrew Huberman
Stanford School of Medicine / Huberman Lab
Caution / warning

I want to be careful here because depression is a serious medical condition, and I'm not recommending Rhodiola as a primary treatment. But it's intriguing that an adaptogen might have genuine effects on mood and stress hormones.

Extracted claim

Huberman notes it is intriguing that an adaptogen might have genuine effects on mood and stress hormones, while cautioning he is not recommending Rhodiola as a primary treatment for depression.

Insufficient evidence to assessHigh confidence

None of the 10 provided studies directly examine Rhodiola rosea's effects on mood or stress hormones (e.g., cortisol) in the context of depression treatment. The available studies focus primarily on e…

Andrew Huberman
Andrew Huberman
Stanford School of Medicine / Huberman Lab
Caution / warning

I want to be careful here because depression is a serious medical condition, and I'm not recommending Rhodiola as a primary treatment. But it's intriguing that an adaptogen might have genuine effects on mood and stress hormones.

Extracted claim

Huberman notes it is intriguing that an adaptogen might have genuine effects on mood and stress hormones, while cautioning he is not recommending Rhodiola as a primary treatment for depression.

Insufficient evidence to assessHigh confidence

None of the 10 retrieved studies provide extractable key findings, populations, or limitations data, making it impossible to directly evaluate Huberman's claim that Rhodiola may have genuine effects o…

Safety, interactions & who should avoid Rhodiola Rosea

generally_recognized_safe

Short-term use of Rhodiola rosea appears to be generally well-tolerated in the RCTs reviewed, with no major safety signals reported. Long-term safety data are limited, and effects in vulnerable populations (pregnant individuals, those on medications affecting the HPA axis or mood) have not been adequately studied.

Rhodiola is generally considered well-tolerated at studied doses; however, its mildly stimulating effects may cause restlessness, irritability, or sleep disturbance, particularly at higher doses or when taken late in the day. Safety data for long-term use, pregnant or breastfeeding individuals, and those with bipolar disorder is limited.

Who should avoid it

Individuals with bipolar disorder, those taking antidepressants or stimulant medications, pregnant or breastfeeding individuals, and those with autoimmune conditions should consult a healthcare provider before use. People sensitive to stimulants should use caution.

Known interactions

  • ·May interact with stimulant medications or other stimulating supplements due to additive stimulant effects
  • ·Potential interaction with antidepressants or serotonergic medications given Rhodiola's possible monoamine-modulating activity
  • ·May influence HPA axis activity, warranting caution with corticosteroids or other hormonal therapies

Pregnancy & breastfeeding

Our sources specifically flag pregnancy or breastfeeding considerations for Rhodiola Rosea — see the cautions above.

We don’t assign pregnancy-safety ratings. Many supplements lack adequate safety data in pregnancy and breastfeeding, and the absence of a warning here does not mean a supplement is safe to take. Don’t start, stop, or continue any supplement while pregnant or nursing without your OB-GYN or midwife.

Read: Supplements during pregnancy & breastfeeding →

This is educational information only. Consult a healthcare provider before starting any supplement.

Stay on top of Rhodiola Rosea research

One email a month when new research on Rhodiola Rosea is published.

Double opt-in · unsubscribe anytime · not medical advice.

No buy link — yet

We only link products that meet our sourcing standards. We haven’t linked one for Rhodiola Rosea yet. Our standards →

Key findings

  • ·Rhodiola rosea is recognized in WFSBP/CANMAT clinical guidelines as a nutraceutical with some evidence for psychiatric and stress-related applications, placing it among the more credentialed herbal supplements in this space.
  • ·A systematic review on HPA axis modulation supports a plausible biological mechanism for Rhodiola's adaptogenic effects in humans, though mechanistic evidence does not confirm clinical outcomes.
  • ·RCTs on physical and athletic performance (including strength, explosive power, and exercise endurance) show mixed or modest results, with at least one study described as exploratory — suggesting benefits in this area are not firmly established.

Evidence gaps

  • ·Most RCTs are short-term and conducted in small, specific populations (e.g., healthy young athletes or adults), leaving long-term effects and generalizability to other demographics — including older adults and clinical populations — largely unknown.
  • ·There is no consistent standardization of Rhodiola extract across studies, making it difficult to determine which formulations, doses, and active compound ratios (e.g., rosavin, salidroside) drive observed effects.
  • ·Direct comparative trials against established treatments for stress, fatigue, or mood disorders are largely absent, making it unclear where Rhodiola fits relative to conventional or other evidence-based interventions.